leisure time -WSS

leisure time

author：entertainment 2025-09-27 10:02:55 - browse：84

Christine Kao/STAT

The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell disease sets up what could be an intense competition between Bluebird Bio, maker of Lyfgenia, and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics, whose drug is Casgevy.

For the first time, physicians and patients will have a choice of potentially curative treatments for an inherited disease that affects nearly 100,000 Americans.

The Vertex/CRISPR team would seem to have the edge. As the first CRISPR-based therapy, Casgevy has the advantage of being powered by the latest and buzziest biological technology, though some physicians and patients may be more comfortable with the lentiviral vector technology behind Lyfgenia, which dates back to the 1990s — even with a “black box” warning of a risk of blood cancer added to its label.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Innovation in antibiotics is ailing. 'Brain drain' may kill it

WSS

Severe heat forecast: Where scorching temperatures will persist over the next week

BMI, flaws aside, is found to be useful estimate of body fat in youth

See how much Covid

Severe heat forecast: Where scorching temperatures will persist over the next week

Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

Burning questions about Delta and the next phase of the Covid pandemic

focus

leisure time

hotspot

Supreme Court strikes down use of affirmative action

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Wildfire smoke exposes gaps in outdoor worker protections

Where does female orgasm come from? Scientists think they know

At least 13 dead in Texas as scorching temps continue

Thousands protest mob assault of women who were paraded naked in remote Indian border state

Guidelines to prevent youth baseball injuries need more muscle

Cord blood banking comes at a high cost to babies

Medicare proposal to cover medical devices draws a mixed reaction

Transgender women dream of pregnancy via uterus transplants

focus

ASCO: AstraZeneca says CAR

Malaysia cuts short music fest after British band slams anti

How a key Senate committee is planning to regulate PBMs

At ASCO, AstraZeneca reports strong data for breast cancer drug

Cord blood banking comes at a high cost to babies

FDA's Pazdur wants cancer trials to range beyond China alone

entertainment

entertainment

hotspot

explore